Yyyyyy x. yyyyyy

Offering 25+ years experience in HIV Medicine & Research

Public Speaking ~ Clinical Research ~ Epidemiology and Prevention

Leadership ~ Direct Patient Care ~ HIV Treatments / Pharmaceuticals

         Excel at steering the complete patient care process from assessment and treatment through to educating patients, family members, community, and healthcare professionals.

         Compassionate and proficient at caring for individuals from diverse cultures and backgrounds gained from vast experience in Kenya, England, Canada, and USA.

         Extensively liaise with all health care team members to increase safety and quality of care.

         Substantial experience in delivering lectures, television interviews, and discussions regarding HIV treatments and studies of HIV pharmaceuticals to physicians, pharmacists, medical students, and affiliated health staff.

         Spoke to medical staff and residents at Broward General Medical Center on management of sepsis and acute life-threatening conditions in patients with HIV presenting to Emergency department (February 2016).

         Presented HIV: A 25-year Snapshot History to American Medical Students Association at FAU Boca Raton in 2010.

         Delivered keynote address on World AIDS Day in 2000 for Community Foundation of Broward County in Ft. Lauderdale.

         Extremely well-versed in social and economic issues associated with HIV, metabolic disorders and complications affecting HIV patients, HIV/Hepatitis C co-infection, and emerging trends in HIV care.

         Multilingual (English, Hindi, Kiswahili, French, and Punjabi); adept at conveying complex information into easy to understandable terms and concepts.

         Formally awarded in 2014 by Board of Directors at world s first AIDS Museum in Ft. Lauderdale for outstanding commitment and care given to HIV community in South Florida.

         Recipient of 2013 Fulgencio Aponte Leadership Award by HIV/AIDS Latino Committee Chair of Broward County and HIV/AIDS Latino Committee of Broward County.

         Ranked as #1 physician in 2010 for having highest patient volume on ADAP (25%) in Broward County.

         Achieved highest overall performance in patient safety outcomes for 2007 to 2008.

         Featured in 2006 issue of International Association of Physicians in AIDS Care (IAPAC).

         Named 2005 Outstanding HIV Physician in Broward County for exhibiting matchless dedication to patients.

         Received proclamation as September 18^th being named Dr. Sheetal Sharma Day by The Office of The Mayor of The City of Ft. Lauderdale.

         Nominated and selected in 2005 to participate in National Physician Ambassadors Program.

AAHIVS (HIV Specialist ), American Academy of HIV Medicine

License #ME0071157, state of Florida

Residency in Internal Medicine, Mercy-Fitzgerald Medical Center/Medical College of Pennsylvania, Darby, Philadelphia, PA

Fellowship: Clinical Fellow Department of Medicine, Division of Special Immunology AIDS Comprehensive Program, University of Miami School of Medicine, Miami, FL

Senior House Officer General Medicine/Coronary Care/Rheumatology/Geriatric Medicine, multiple hospitals

Diagnostic Radiology, St. Mary s Hospital, University of London, London, England; University of London/Royal College of Radiologists, London, W.I,. England

Residency in Diagnostic Radiology, Kenyatta National Hospital, Nairobi, Kenya

Resident I in General Surgery, Cardiovascular and Thoracic Surgery, Surgical Intensive Care, McGill University Teaching Hospital, Montreal, Canada

Rotating Internship in Medicine, Infectious Diseases, General Surgery, Pediatric Medicine, Obstetrics and Gynecology, Kenyatta National Hospital, University of Nairobi (teaching hospital), Nairobi, Kenya

Doctor of Medicine, University of Nairobi, Kenya (accredited medical school)

Bachelor of Science in Biology, McMaster University, Ontario, Canada

Comprehensive Care Center, Broward Health, Ft. Lauderdale, FL, 1998 to Present

Physician & Clinical Investigator

         Deliver top-quality medical care with specialization in serving HIV-infected patients.

         Concurrently function as clinical investigator, exhibiting exceptional analytical and documentation skills.

         Treat patients according to high standards of care, and explain procedures in understandable terms.

         Educate caseload of 900+ patients in subjects spanning self-care, available medications, and nutrition.

Prior Roles:

Medical Director, Center for Special Immunology (HIV), Ft. Lauderdale, Florida

Senior House Officer, Various Hospitals, London, Bedford, Portsmouth, England

Clinical Attachment Intensive Care Medicine, Kenyatta National Hospital, Nairobi, Kenya

Senior House Officer, Genito Urinary Medicine, Charing Cross Hospital, London, University of London

Clinical Attachment (Registrar) Diagnostic Radiology, St. Mary s Hospital, London, University of London

As Principal Investigator:

GS-US-236-0102: A Phase III, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumerate/GS-9350 Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumerate in HIV-1 infected, Antiretroviral Treatment-Na ve Adults

GS-US-236-0103: A Phase III, Randomized, Double-Blind, Study to Evaluate the Safety and Efficacy of Elvitegravir/ Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

GS-US-216-0114: A Phase III Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically Suppressed, HIV 1 Infected Patients

GS-US-264-0106: A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to FTC/RPV/TDF Fixed-dose Regimen in Virologically Suppressed, HIV 1 Infected Patients

GS-US-264-0110: A Phase 3b, Randomized, Open-label Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared with a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Infected, Antiretroviral Treatment-Na ve Adults.

ING112574: A Phase III study to demonstrate the antiviral activity and safety of GSK 1349572 in HIV -1-infected adult subjects with treatment failure on an integrase inhibitor containing regimen

GS-US-164-0216: SWIFT study: A prospective, randomized, open-label phase IV study

to evaluate the rationale of switching from fixed-dose abacavir (ABC) Lamivudine (3TC) to fixed dose tenofovir DF (TDF) emtricitabine (FTC) in virologically-suppressed, HIV-1 infected patients maintained on a ritonavir-boosted protease inhibitor-containing antiretroviral regimen.

TIPRANIVIR BIPI 1181.99: Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500 mg/200 mg BID in antiretroviral treatment experienced HIV-positive patients with HCV or HBV co-infection, with a pilot evaluation of therapeutic drug monitoring (TDM). An open-label, multicenter, multinational trial with randomization to standard of care (SOC) or TDM TPV/r therapy.

Merck INTEGRASE INHIBITOR MK0518: Evaluation and treatment of patients who would benefit from this in expanded access.

COMET: Phase 10 evaluation of switching from twice a day to a simplified once a day Truvada regimen, in virologically suppressed HIV-infected patients taking Sustiva.

Abbott M05-730: A phase III, open-label, randomized, multiple center, multi-country study designed to demonstrate the safety, tolerability, pharmacokinetics and antiviral activity of Lopinavir/Ritonavir in tablet formulation when dosed QD vs BID in combination with nucleoside reverse transcriptase inhibitors in the treatment of antiretroviral na ve, HIV-1 infected subjects.

Merck HIV DRUG RESISTANCE: Prevalence of antiretroviral drug resistance in treatment na ve HIV-positive patients: A multi-center study.

GS-US-164-0107: Combination of Efavirenz and Truvada (The COMET Study); A phase 4 evaluation of switching from twice daily Zidovudine and Lamivudine (Combivir ) to a simplified, once-daily regimen of co-formulated Emtricitabine and Tenofovir Disproxil Fumarate (Truvada ), in virologically suppressed, HIV-infected patients taking Efavirenz.

ML-18018: A 12 week, prospective, open-label, multicenter, Cohort study to assess HIV-patient quality of life and tolerability after administration of Enfuvirtide-containing HAART (QUALITE Study).

COL102060: An open-label, multicenter study to evaluate the efficacy and safety of a fixed-dose combination of Abacavir 600 mg/Lamivudine 300 mg once-daily in combination with Atazanavir 300 mg + Ritonavir 100 mg once daily in antiretroviral-na ve HIV-1 infected subjects over 48 weeks.

BMS 1454-158: A comparison of HIV RNA suppression produced by triple combination regimens containing either didanosine enteric coated or didanosine tablet formulation each administered once daily. Poster displayed at 8^th Retrovirus Conference in Chicago, IL, 2001.

M98-863: A randomized, double-blind, Phase III study of ABT-378/Ritonavir plus stavudine and Lamivudine vs Nelfinavir plus stavudine and lamivudine in antiretroviral-na ve HIV infected subjects.

M98-888: A Randomized, open-label, Phase III study of ABT-378/Ritonavir in combination with nevirapine and two nucleoside reverse transcriptase inhibitors (NRTIs) vs investigator selected protease inhibitor(s) in combination with nevirapine and two NRTIs in antiretroviral-experienced HIV infected subjects.

- A clinical pharmacist managed prescription renewal and intervention program at an Ambulatory HIV clinic.

- Evaluation of Atorvastatin and pharmacy-based interventions for management of Hypetriglyceridemia in HIV-1 infected patients.

SALK 806: A multicenter, double-blind, phase III, adjuvant-controlled study of the effect of 10 units of HIV-1 immunogen (REMUNE ) compared to IFA alone every 12 weeks on AIDS and HIV-progression-free survival in subjects with HIV infection and CD4 T lymphocytes between 300 and 549 cells/ L regardless of concomitant HIV therapies.

SALK 903: An expanded access open-label protocol of remune in HIV-1 infected subjects.

VIRA 3001: An open-label randomized trial comparing the effect on viral load of standard HIV treatment practice (delayed phenotyping) with treatment based on the antivirogram (immediate phenotyping).

PR 97-20-010: The effect of PROCRIT (epoetin alfa) on the quality of life in HIV infected patients.

VIRA 3001: An open-label randomized trial comparing the effect on viral load of standard HIV treatment practice (delayed phenotyping) with treatment based on the antivirogram (immediate phenotyping).

PR 97-20-010: The effect of PROCRIT (epoetin alfa) on the quality of life in HIV infected patients.

PR 98-29-002: The effect of a weekly dosing regimen of PROCRIT (epoetin alfa) on the quality of life in the treatment of anemia in HIV infected patients on antiretroviral therapy.

PRO 3001: Amprenavir (191W94) open-label protocol of subjects with HIV-0000 xxxxxx xxxx , xxxx , xxxxx 00000: An open-label study to evaluate the safety and tolerance of Amprenavir (141W94) and Abacavir combination therapy in protease inhibitor experiences subjects with HIV-1 infection who are failing their current antiretroviral treatment regimen.

BI TRIAL 1181.12 (RESIST) 1): A Phase III, randomized, open-label, comparative safety and efficacy study of Tipranavir boosted with low-dose Ritonavir (TPN/RTV) versus genotypically-defined protease inhibitor (PI/RTV) in multiple antiretroviral drug-experienced patients (RESIST 1: Randomized evaluation of strategic intervention in multi-drug resistant patient with Tipranavir.

As Clinical Sub-investigator:

A4001027: A multicenter, randomized, double-blind, placebo-controlled trial of a novel CCR5 antagonist, UK-427,857, in combination with optimized background therapy versus optimized background therapy alone for the treatment of antiretroviral experienced HIV-1 infected subjects.

TMC278-C209: A phase 3, randomized, double-blind study of TMC278 25mg daily versus efavirnez 600mg daily in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricitabine in antiretroviral-na ve HIV-1 infected subjects.

TMC114HIV4023: A multicenter, open-label, randomized study to assess the metabolics, efficacy, and safety of once-daily darunavir versus atazanavir in HIV infected treatment na ve adult patients.

GS-US-236-0104: A phase 2, randomized, double-blind study of the safety and efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 versus Atripla (Efavirenz 600mg/Emtricitabine 200mg/Tenofovir Disoproxil Fumarate 300mg) in HIV-1 infected, antiretroviral treatment-na ve adults.

GS-US-183-0145: A multicenter, randomized, double-blind, double-dummy, phase 3 study of the safety and efficacy of titonavir-boosted Elvitegravir (EVG/r) versus Raltegravir (RAL) and administered with a background regimen in HIV-1 infected, antiretroviral-experienced adults.

GS-US-236-0118: A Phase 0000 xxxxxx xxxx , xxxx , xxxxx 0000095: A multicenter, randomized, double-blind, comparative trial of Maraviroc + Darunavir/Ritonavir versus Emtricitabine/Tenofovir + Darunavir/Ritonavir for the treatment of antiretroviral-Na ve HIV-Infected patients with CCR5-Tropic HIV -1

GS-US-183-0130: A phase 2, open-label, multicenter study of the safety of Ritonavir-boosted GS 9137 (GS 9137/r administered in combination with other antiretroviral agents for the treatment of HIV-1 infected subjects.

TMC114-C211 (ARTEMIS): A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in a treatment-naive HIV-1 infected subjects.

TMC114-C226: Early access of TMC114 in combination with low-dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options.

TIBOTEC TMC125-C206: A phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects with limited to no treatment options.

IMPACT: Phases IV, multi-center, cross sectional study to evaluate the I50L, substitution among subjects experiencing virology failure on a HAART regimen containing Atazanavir (ATV).

NV17751: Observational cohort study of pneumonia in Fuzeon exposed and non-exposed patients.

BMS AI424-131: A phase IV. Open-label, randomized trial assessing a Reyataz-based substitution approach in the management of Lipodystrophy Syndrome.

BMS A1424-103: A phase IIIB open-label randomized study comparing the antiviral efficacy, safety, and effect on serum lipids of Atazanavir/Ritonavir versus Lopinavir/Ritonavir, each in combination with Tenofovir and either Didanosine EC or Staudine XR in HIV-1 infected subjects receiving a NNRTI containing HAART regimen who are experiencing their first virologic failure.

TMC114-C202: A phase II randomized, controlled, partially blinded, 48-week trial to investigate dose response of TMC114/RTV in 3-class experienced, multi PI experienced HIV-1 related subjects.

BI TRIAL 1182.51: An open-label, randomized, parallel group pharmacokinetics trial of Tipranavir/Ritonavir (TPV/RTV), alone or in combination with RTV-boosted Saquinavir (SQV), Amprenavir (APV) or Lopinavir (LPV), plus an optimized background regimen, in multiple antiretroviral (ARV) experienced patients.

PRO 30012: To determine the effect of APV on lipid metabolism (hyperlipoidemia and lipodystrophy) in subjects experiencing these adverse events and who are currently not failing current antiretroviral therapy and to provide open-label, pre-approved access to APV for adults and adolescents >13 years with HIV infection with limited treatment option.

ICC 601U: A Phase II, 24 week, open-label study designed to evaluate the pharmacokinetics, safety, tolerability, and efficacy of novel combination therapy with Videx (Didanosne), Zerit (Stavudine), Viramune (Nepirapine), and MKC-442 (with or without hydroxyurea) for the treatment of HIV-1 infection in non-nucleoside reverse transcriptase inhibitor na ve patients who failed previous protease inhibitor treatment.

ICC 602: A Phase II, 48 weeks, open-label study designed to evaluate the safety, tolerability, and efficacy of a simplified dosing regimen of VIRACEPT (Nelfinavir, Mesylate) 1250 mg BID, Crixivan (Indinavir sulfate) 1200 mg q12h, and Sustiva (Efavirenz, DMP-266) 600 mg q24h for the treatment of HIV-1 infection in non-nucleoside reverse transcript inhibitor and protease inhibitor na ve patients.

DMP 266-049: A Phase IV, open-label, randomized, multicenter study to determine the safety and duration of viral suppression of continued therapy with one or two protease inhibitors + two nucleoside analogue reverse transcriptase inhibitor regimen vs. substitution therapy with patients.

COLA 4005: A Phase II, open-label, randomized study of the efficacy and safety of Epivir 150 mg BID vs Epivir 300 mg once daily when administered for 24 weeks in combination with FDA approved dosage regimens of zerit and either Crixivan or Viracept in subjects with HIV-1 infection.

BMS 1661-201: A pilot, phase II, double-blind study to assess the virologic effect of REMUNE vs incomplete Freund s Adjuvant (IFA) in patients who are infected with Human Immunodeficiency virus type 1 (HIV-1), have a plasma HIV-1 RNA level less than 50 copies/mL, are receiving highly active antiretroviral therapy (HAART), and who subsequently discontinue HAART regimen.

BMS 2000: A study of the combination of Indinavir, Ritonavir, Enteric-coated DDI and d4T in nucleoside and non-nucleoside reverse transcriptase inhibitor experienced patients; investigating differences between women and men.

AG1343-1127U: randomized, open-label study of Nelfinavir or Efavirenz in HIV-1 infected antiretroviral na ve patients.

BMS008: Evaluation of the safety and antiviral efficacy of a novel HIV-0000 xxxxxx xxxx , xxxx , xxxxx 00000: A phase IV, multicenter of the efficacy and safety of 48 week induction treatment with TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg combination tablet (BID) + Efavirenz (600mg QD) followed by 48 week randomized, open-label, maintenance treatment with TRIZIVIR + Efavirenz in HIV-1 infected antiretroviral therapy na ve subjects.

BMS 034: A phase III study comparing the antiviral efficacy and safety of BMS 0000 xxxxxx xxxx , xxxx , xxxxx 00000: A phase III, randomized, multicenter, parallel group, open-label, three arm study to compare the efficacy and safety of two dosing regimens of GW433908/Ritonavir 700mg/100mg twice daily or 1400mg/200 once daily vs Lopinavir/Ritonavir 400mg/100mg twice daily for 48 weeks in protease inhibitor experienced HIV-infected adults experiencing virological failure.

BMS006 randomized, open-label trial comparing tolerability of Videx EC capsules to Videx tablets in adults with HIV

GS99-903: A phase III, randomized, double-blind, multicenter study of the treatment of antiretroviral-na ve, HIV-infected patients comparing Tenofovir Disoproxil Fumarate administered in combination with Lamivudine and Efavirenz vs Stavudine, Lamivudine and Efavirenz.

ESS40006: A phase II, randomized, open-label comparative study of two different dosage regimens of Amprenavir (900mg BID vs 600mg BID) in combination with Ritonavir (100mg BID) plus Abacavir, another NRTI, and either Efavirenz or Tenofovir DF in HIV infected subjects with virologic evidence of treatment failure.

ESS40009: A phase IV, open-label study to assess the safety and tolerability of Abacavir (ZIAGEN) in HIV-1 infected individuals and to investigate the effect of baseline genotype with virtual phenotype on the response to Abacavir (ZIAGEN) in therapy experienced subjects in the clinical setting.

ESS40010: Glaxo Welcome trial to assess the regression of hyperlactemia and to evaluate the regression of established Lipodystrophy in HIV (+) subjects (TARHEEL).

BIPI 1182.17U: A long term open-label rollover trial assessing the safety and tolerability of combination Tipranavir and Ritonavir use in HIV-1 infected subjects.

BIPI 1182.51: An open-label, randomized, parallel group pharmacokinetics trial of Tipranavir/Ritonavir (TPV/RTV, alone or in combination with RTV-boosted Saquinavir (SQV), Amprenavir (APV) or Lopinavir (LPV), plus an optimized background regimen, in multiple antiretroviral (ARV) experienced patients.

BIPI 1182.12 (RESIST 1): study of Tipranavir boosted with low-dose Ritonavir (TPN/RTV) versus genotypically-defined protease inhibitor (PI/RTV) in multiple antiretroviral drug-experienced patients (RESIST 1: Randomized evaluation of strategic intervention in multi drug resistant patient with Tipranavir).

ESS30008: A phase III, 48-week, open-label, randomized, multicenter study of the safety and efficacy of the Abacavir /Lamivudine fixed-dose combination tablet administered QD versus Abacavir + Lamivudine administered BID in combination with a PI or NNRTI in antiretroviral experienced patients.

APV30005: study to assess the long term safety profile of GW433908 containing regimens in HIV-1 infected subjects.

GS-01-934: study of the treatment of antiretroviral-na ve, HIV-1 infected subjects comparing Tenofovir Disoproxil, Fumarate and Emtricitabine in combination with Efavirenz versus Combivir (Lamivudine/Zidovudine) and Efavirenz.

AI424067: evaluating effect on serum lipids following a switch to the protease inhibitor (PI) Atazanavir in HIV-1 infected subjects evidencing virologic suppression on their first PI-based antiretroviral therapy.

Current: Gilead Sciences, Janssen Pharmaceuticals, Merck Pharmaceuticals

Past: DuPont Pharmaceuticals, Agouron Pharmaceuticals, Glaxo-Wellcome Pharmaceuticals,

Abbvie Pharmaceuticals, Bristol-Myers Squibb Pharmaceuticals, Ortho Biotech

International AIDS Society, American Academy of HIV Medicine

Yyyyyy x. yyyyyy

DATE

HIRING AGENT NAME

TITLE

COMPANY NAME

ADDRESS

CITY/STATE/ZIP CODE

Dear__________________:

I am currently seeking a challenging career opportunity as a Medical Director and am submitting my resume for your review. In advance, thank you for your time and consideration.

I am excited to build a rewarding career with your organization, and can offer cross-functional leadership experience in clinical research, speaking engagements, medical education, patient advocacy, and pharmaceutical products. I ve sat on countless advisory boards and committees focused on quality improvements and enhancing patient care outcomes, especially for those affected by HIV.

To complement my professional background, my academic achievements include an HIV Specialist credential and a Medical Doctor degree.

Currently, as a primary care physician at Comprehensive Care Center, Broward Health, I leverage my advanced knowledge of cutting-edge therapeutic options to treat HIV-infected patients, while also serving as a clinical investigator with a focus on HIV care.

As this is just a sampling of my job history, please refer to the accompanying resume for additional experience. I look forward to speaking with you personally, as I believe the sum of these aforementioned reasons will prove me to be a valuable asset to your organization. Thank you for your consideration.

Sincerely,

Yyyyyy x. yyyyyy